Louis Reese

Louis Reese is one of our two co-founders and is the Executive Chairman of the Company. Mr. Reese has served in this role for the Company since September 2014. Mr. Reese has also been a member of the executive committee of UBI since 2014. He was also a director of ShenLian Biotech from 2010 to 2014. Mr. Reese is also the co-founder of an investment and advisory firm with active investments in real estate, energy, hospitality and life sciences. His investments focus on achieving global impact in critical important areas through innovative models and approaches. He received his B.A. from University of Pennsylvania.

Chairman of the Board
Mei Mei Hu

Mei Mei is Chief Executive Officer and Co-Founder of Vaxxinity and is also a member of the executive committee of United Biomedical, Inc. She has overseen the launch of one of the first endobody vaccines in the world and the successful spin-out of five companies, including Vaxxinity’s IPO on NASDAQ. She currently leads an active pipeline of chronic disease immunotherapeutic candidates including for Alzheimer’s, Parkinson’s, and hypercholesterolemia as well as variant-inclusive COVID booster. Mei Mei was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues. Mei Mei is also co-founder of an investment and advisory group with active investments in real estate, energy and life sciences. She has been named to Time 100 Next list, Fortune 40 under 40, and is a member of the Young Global Leaders of World Economic Forum. She holds a B.A. from University of Pennsylvania and her J.D. from Harvard Law School

Peter Diamandis

Peter Diamandis is a director of the Company. Dr. Diamandis has been a director of the Company since the Reorganization and was previously a director of COVAXX since March 2020. Dr. Diamandis has been the Chief Executive Officer of PHD Ventures, Inc., his personal holding company for his writing, speaking and consulting activities, since October 1993. Dr. Diamandis has started more than 24 companies in the areas of human longevity, space, venture capital and education, including as a co-founder of BOLD Capital Partners in 2015, a venture fund investing in exponential technologies, and as the founder and Executive Chairman of the XPRIZE Foundation, a non-profit foundation which, since 1996, has designed and operated large-scale incentive competitions for the development of new technologies that may help solve some of mankind’s major challenges. In the area of human longevity, he has helped found Human Longevity, Inc., for which he served as a director from 2013 until December 2018, Celularity Inc., for which he served as Vice Chairman from July 2017 to July 2021 and as a director starting in July 2021, and Fountain Therapeutic Services, Inc., for which he has served as Chairman since January 2019. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution founded in 2010 that counsels the world’s leaders on exponentially growing technologies. He also serves as a director of two special purpose acquisition companies: DPCM Capital, Inc., which completed its initial public offering in October 2020, and Software Acquisition Group Inc. II, which completed its initial public offering in September 2020. Dr. Diamandis is also a New York Times bestselling author. He earned degrees in Molecular Engineering and Aerospace Engineering from Massachusetts Institute of Technology and holds an M.D. from Harvard Medical School.

Member of the Compensation Committee
Chair of the Nominating and Corporate Governance Committee
George Hornig

Mr. Hornig is currently Chairman of Xometry, an AI-driven platform for on-demand manufacturing of industrial parts and Co-Chairman (and Audit Chairman) of Healthwell Acquisition Corp., a special purpose acquisition company. Mr. Hornig is also Managing Partner and Co-Founder of The Seed Lab, an early-stage venture fund. From 2010-2016, Mr. Hornig was Senior Managing Director and COO of PineBridge Investments (formerly AIG Investment Management). Prior to joining PineBridge, Mr. Hornig spent 11 years at Credit Suisse Asset Management as Managing Director and Global COO. From 1993-1999, Mr. Hornig was Executive Vice President of Deutsche Bank Americas. Earlier in his career Mr. Hornig was Managing Director and COO of Wasserstein Perella & Co., worked in the M&A group of First Boston and was an Associate with the law firm of Skadden, Arps. During his career, Mr. Hornig has served as a Director of Forrester Research, Unity Mutual Life, Veridian Group, KBL Merger Corp IV, Office Tiger, Daily Candy and Merchants Preferred. Mr. Hornig received his A.B., J.D. and M.B.A. from Harvard University.

Chair of the Audit Committee
Peter Powchik
Peter has been associated with Vaxxinity and United Neuroscience since 2018. His expertise includes clinical development, translational medicine, and building research organizations. Prior to joining United Neuroscience he was SVP Head of Clinical Development at Regeneron Pharmaceuticals from 2006-2018 where he oversaw the development and approval of Regeneron’s first seven drugs and helped build its development and regulatory infrastructure. He is also formerly EVP of Clinical Development, Chugai USA; VP of Clinical Development and Medical Affairs, US at Novartis overseeing the development and approval of Ritalin LA and Focalin; and Senior Director at Sepracor where he initiated the development of Lunesta. He is a board certified psychiatrist having trained at NYU School of Medicine, Mt Sinai Medical Center (NYC), and Columbia University College of Physicians and Surgeons.
Katherine Eade, JD

Katherine Eade, JD, who has more than 20 years of experience advising public companies on M&A, corporate governance and capital markets, including a dozen years serving in leadership roles in the life sciences industry. She currently serves as an independent director on the board of directors of Harvard Bioscience, Inc., since 2017, and is a member of its Audit Committee and Chair of its Governance Committee. She began her career as an attorney at Cleary Gottlieb, a leading international law firm.

Member of the Audit Committee
Landon Ogilvie

Landon Ogilvie, who has more than 25 years of experience in logistics, risk management, operations management, and organizational leadership across diverse industries. He currently serves as CEO of Co-West Inc. and Destination Systems, the largest independently owned logistics company in Colorado serving CDOT, US Department of Defense and many state municipalities. He began his career from the risk management sector where he was a partner with one of the oldest businesses in Texas, Gans and Smith Insurance.

Member of the Compensation Committee
James Smith

James Smith, who has more than 20 years of experience in financial and business development at various growth companies. James’ primary roles have revolved around governance, reporting, business development, sales, M&A and capital raising. He currently serves as CEO of InvitedHome and Board member of YourFare. He began his career as an auditor at Ernst & Young.

Member of the Audit Committee
Gaby Toledano

Gaby Toledano, who has more than 30 years of experience as a Board member, advisor and operating executive. She is currently Chief Operating Officer at Keystone Strategy and serves on the Boards of Lilium and Velo3D where she chairs the Compensation Committees of both companies. Prior to that, she served as Chief People Officer at Tesla and EVP and Chief Talent Officer at Electronic Arts and Siebel Systems.

Chair of the Compensation Committee
Member of the Nominating and Corporate Governance Committee